Abbott seeks appeal on royalties to UK's Cambridge
Tuesday, 15 February, 2005
Abbott Laboratories is seeking to appeal a British court ruling that granted Cambridge Antibody Technology a greater percentage of royalties on Abbott's arthritis drug Humira.
In December, UK Judge Hugh Laddie said Abbott should pay Cambridge a royalty of just over 5 per cent on sales of Humira, compared with the royalty of 2 per cent of net sales it has been paying.
The application will be considered by one Court of Appeal judge, Cambridge said in a statement. If the application is unsuccessful, Abbott will be entitled to request a hearing.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
